IFN-β treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing -remitting multiple sclerosis

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system probably mediated by Th1 lymphocytes. IFN-b is an established therapy for relapsing MS patients, although the mechanisms underlying its efficacy are yet to be well characterized. We determined IL-2 production, CD25 expression and T-cell proliferation from relapsing -remitting MS patients before and three months after starting therapy. A decrease in the percentage of CD80-induced IL-2-producing cells was observed after in vivo IFN-b treatment. These data support that one of the immunomodulatory effects of IFN-b treatment in MS may be a limitation of the autoimmune response modifying the CD80:CD28/CTLA-4 pathway.

Keywords

CD28 CD80 CD86 IFN-β IL-2 multiple sclerosis

Get full access to this article

View all access options for this article.

References

Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system . Cell 1996; 85: 299-302 .

Bluestone JA. New perspectives of CD28-B7 mediated T cell costimulation . Immunity 1995; 2: 555-559 .

Thompson CB. Distinct roles for the costimulation ligands B7- 1 and B7-2 in T helper cell differentiation . Cell 1995; 81: 979-982 .

Liu Y , Linsley PS. Co-stimulation of T cell growth . Curr Opin Immunol 1992; 4: 265-270 .

Boise LH , Minn AJ , Noel PJ , June CH , Accavitti MA , Lindsten T et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL . Immunity 1995; 3: 87-98 .

Hohlfeld R. Therapeutic strategies in multiple sclerosis I . Immunotherapy Philos Trans R Soc Lond B Biol Sci 1999; 354: 1697-1710 .

Interferon Beta-1b Study Group . Interferon Beta-1b in the treatment of multiple sclerosis - final outcome of the randomised control trial . Neurology 1995; 45: 1277-1285 .

Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group . N Engl J Med 2000; 343: 898-904 .

PRIMS (Prevention of relapses and disability by interferon beta-1a for relapsing multiple sclerosis) study group: PRIMS-4 . Long-term efficacy of interferon-beta-1a in relapsing MS . Neurology 2001; 56: 1628-1636 .

10.

Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study group . Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results . Neurology 2001; 56: 1496-1504 .

11.

Genç K , Dona DL , Reder AT. Increased CD80 - B cells in active multiple sclerosis and reversal by interferon b-1b therapy . J Clin Invest 1997; 99: 2664-2671 .

12.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

13.

Lanier LL , O’Fallon S , Somoza Ch , Phillips JH , Linsley PS , Okumura K et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL . J Immunol 1995; 154: 97-105 .

14.

Liu Z , Pelfrey CM , Cotleur A , Lee J-C , Rudick RA. Immunomodulatory effects of interferon beta-1a in multiple sclerosis . J Neuroimmunol 2001; 112: 153-162 .

15.

Giorelli M , Livrea P , Defazio G , Ricchiuti F , Pagano E , Trojano M. IFN-beta 1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms . J Interferon Cytokine Res 2001; 21: 809-812 .

16.

Rudick RA , Carpenter CS , Cookfair DL , Tuohy VK , Ransohoff RM. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta . Neurology 1993; 43: 2080-2087 .

17.

Noronha A , Toscas A , Jensen M. Interferon b decreases T cell activation an interferon g production in multiple sclerosis . J Neuroimmunol 1993; 46: 145-154 .

18.

Pette M , Pette DF , Muraro PA , Farnon E , Martin R , McFarland HF. Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific T-helper type 1 lymphocytes . Neurology 1997; 49: 385-392 .

19.

Weber F , Polak T , Gunther A , Kubuschok B , Janovskaja J , Bitsch A et al. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing -remitting multiple sclerosis . Ann Neurol 1998; 44: 27-34 .

20.

Leppert D , Waubant E , Burk MR , Oksenberg JR , Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis . Ann Neurol 1996; 40: 846-852 .

21.

Ferrarini AM , Sivieri S , Bulian P , Butarello M , Biasi G , Tavolato B et al. Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients . J Neuroimmunol 1998; 84: 213-217 .

22.

Ferrarini AM , Sivieri S , Butarello M , Facchinetti A , Perini P , Gallo P. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-b 1 b-treatment multiple sclerosis patients . Mult Scler 1998; 4: 174-177 .

23.

Inogés S , Merino J , Bandrés E , De Castro P , Subirá ML , Sánchez-Ibarrola A. Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients . Clin Exp Immunol 1999; 115: 521-525 .

24.

Rep MH , Schrijver HM , van Lopik T , Hintzen RQ , Roos MT , Ader HJ et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma Sa producing T cells in MS patients . J Neuroimmunol 1999; 96: 92-100 .

25.

Clerici M , Saresella M , Trabattoni D , Speciale L , Fossati S , Ruzzante S et al. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease . J Neuroimmunol 2001; 121: 88-101 .

26.

Ewan PW. New insight into immunological mechanisms of venom immunotherapy . Curr Opin Allergy Clin Immunol 2001; 1: 367-374 .

27.

Strle Z , Zhou JH , Shen WH , Broussard SR , Johnson RW , Freund GC et al. Interleukin-10 in the brain . Crit Rev Immunol 2001; 21: 427-449 .

28.

Nicoletti F , Di Marco R , Patti F , Zaccone P , L’Episcopo MR , Reggio E et al. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL- 1beta, IL-2, IL-4 and tumour necrosis factor-alpha . Cytokine 2000; 12: 682-687 .